Abstract: Systems and methods for providing an intelligent network to onboard patients to specialty medications are described herein. A server system for enrolling patients into a patient engagement service may be configured to receive an electronic indication of a trigger event message, the trigger event message associated with a patient identified with patient context data, a therapy for the patient identified with a therapy identifier, and a sponsor of the therapy identified with a sponsor identifier; determine, based on the sponsor identifier, the patient context data, and the therapy identifier, whether the patient engagement service is available and supported for the sponsor; and initiate the patient engagement service.

Abstract: Systems and methods for providing an intelligent network to onboard patients to specialty medications are described herein. A server system for managing communication is configured to receive from a user at a healthcare practice, an electronic request to obtain a medical prior authorization (medPA) for a specialty drug to administer for a patient of the healthcare practice; select, using a rules service, a communication pathway to submit the medPA to a healthcare payer from a plurality of communication pathways; and initiate a connection with the healthcare payer using the selected communication pathway.

Abstract: Systems and methods for providing an intelligent network to onboard patients to specialty medications are described herein.

Abstract: The present invention relates to a process for the preparation of lasmiditan, a compound of formula I, or pharmaceutically acceptable salts thereof, the process comprising reacting a compound of formula IV with morpholine to obtain a compound of formula II, reacting the of formula III with a compound of formula IIA to obtain lasmiditan or salt thereof.

Abstract: The present invention relates to process for preparation of N1-(5-Chloropyridin-2-yl)-N2-[(1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo [5,4-c]pyridin-2-ylcarboxamido)cyclohexyl]oxamide p-toluene sulfonate monohydrate [edoxaban tosylate monohydrate], the compound of formula I, comprising reacting compound of formula VI with compound of formula V to obtain the compound of formula IV and further converting it to edoxaban tosylate monohydrate in an industrially feasible process.

Abstract: Solid state forms of Eltrombopag choline, processes for preparation thereof and pharmaceutical compositions thereof are disclosed.

Abstract: Solid state forms of Eltrombopag choline, processes for preparation thereof and pharmaceutical compositions thereof are disclosed.

Abstract: Process for efficiently operating a natural gas liquefaction system with integrated heavies removal/natural gas liquids recovery to produce liquefied natural gas (LNG) and/or natural gas liquids (NGL) products.

Abstract: Process for efficiently operating a natural gas liquefaction system with integrated heavies removal/natural gas liquids recovery to produce liquefied natural gas (LNG) and/or natural gas liquids (NGL) products.